Log in

NASDAQ:MIST - Milestone Pharmaceuticals Stock Price, Forecast & News

$16.74
+0.46 (+2.83 %)
(As of 12/8/2019 04:34 AM ET)
Today's Range
$16.35
Now: $16.74
$17.23
50-Day Range
$16.03
MA: $18.50
$21.73
52-Week Range
$15.09
Now: $16.74
$27.95
Volume4,582 shs
Average Volume20,808 shs
Market Capitalization$410.01 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Milestone Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes drugs for the treatment of cardiovascular indications. It offers Etripamil that completed Phase 2 clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for treating Atrial Fibrillation and Angina. The company was founded in 2003 and is headquartered in Montréal, Canada.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MIST
CUSIPN/A
CIKN/A
Phone514-336-0444

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Net Income$-23,180,000.00

Miscellaneous

Employees20
Market Cap$410.01 million
Next Earnings Date2/12/2020 (Estimated)
OptionableNot Optionable

Receive MIST News and Ratings via Email

Sign-up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter.


Milestone Pharmaceuticals (NASDAQ:MIST) Frequently Asked Questions

What is Milestone Pharmaceuticals' stock symbol?

Milestone Pharmaceuticals trades on the NASDAQ under the ticker symbol "MIST."

How were Milestone Pharmaceuticals' earnings last quarter?

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) issued its quarterly earnings results on Wednesday, November, 13th. The company reported ($0.52) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by $0.04. View Milestone Pharmaceuticals' Earnings History.

When is Milestone Pharmaceuticals' next earnings date?

Milestone Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 12th 2020. View Earnings Estimates for Milestone Pharmaceuticals.

What price target have analysts set for MIST?

5 analysts have issued twelve-month target prices for Milestone Pharmaceuticals' shares. Their forecasts range from $26.50 to $32.00. On average, they expect Milestone Pharmaceuticals' share price to reach $30.10 in the next year. This suggests a possible upside of 79.8% from the stock's current price. View Analyst Price Targets for Milestone Pharmaceuticals.

What is the consensus analysts' recommendation for Milestone Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Milestone Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Milestone Pharmaceuticals.

Has Milestone Pharmaceuticals been receiving favorable news coverage?

Media headlines about MIST stock have been trending somewhat positive on Sunday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Milestone Pharmaceuticals earned a daily sentiment score of 2.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Milestone Pharmaceuticals.

Are investors shorting Milestone Pharmaceuticals?

Milestone Pharmaceuticals saw a decrease in short interest in November. As of November 15th, there was short interest totalling 19,200 shares, a decrease of 11.9% from the October 31st total of 21,800 shares. Based on an average daily volume of 7,500 shares, the days-to-cover ratio is currently 2.6 days. Currently, 0.2% of the company's stock are short sold. View Milestone Pharmaceuticals' Current Options Chain.

Who are some of Milestone Pharmaceuticals' key competitors?

What other stocks do shareholders of Milestone Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Milestone Pharmaceuticals investors own include eHealth (EHTH), Aeglea Bio Therapeutics (AGLE), Applied Therapeutics (APLT), Aqua Metals (AQMS), CareDx (CDNA), Iovance Biotherapeutics (IOVA), LYFT (LYFT), Opko Health (OPK), Tandem Diabetes Care (TNDM) and Tesla (TSLA).

Who are Milestone Pharmaceuticals' key executives?

Milestone Pharmaceuticals' management team includes the folowing people:
  • Mr. Joseph G. Oliveto, CEO, Pres & Director (Age 51)
  • Dr. Philippe Douville, Founder & Chief Scientific Officer (Age 57)
  • Mr. Timothy L. Maness, VP of Fin. (Age 59)
  • Dr. Francis Plat, Chief Medical Officer (Age 61)
  • Mr. Lorenz Muller, Chief Commercial Officer (Age 55)

When did Milestone Pharmaceuticals IPO?

(MIST) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

When did the company's lock-up period expire?

Milestone Pharmaceuticals' lock-up period expired on Tuesday, November 5th. Milestone Pharmaceuticals had issued 5,500,000 shares in its public offering on May 9th. The total size of the offering was $82,500,000 based on an initial share price of $15.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the expiration of the lock-up period.

Who are Milestone Pharmaceuticals' major shareholders?

Milestone Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Millennium Management LLC (0.10%). Company insiders that own Milestone Pharmaceuticals stock include Holdings A/S Novo, Rtw Investments, Lp and Stonepine Capital, LP. View Institutional Ownership Trends for Milestone Pharmaceuticals.

Which institutional investors are buying Milestone Pharmaceuticals stock?

MIST stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC. Company insiders that have bought Milestone Pharmaceuticals stock in the last two years include Holdings A/S Novo, Rtw Investments, Lp and Stonepine Capital, LP. View Insider Buying and Selling for Milestone Pharmaceuticals.

How do I buy shares of Milestone Pharmaceuticals?

Shares of MIST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Milestone Pharmaceuticals' stock price today?

One share of MIST stock can currently be purchased for approximately $16.74.

How big of a company is Milestone Pharmaceuticals?

Milestone Pharmaceuticals has a market capitalization of $410.01 million. Milestone Pharmaceuticals employs 20 workers across the globe.View Additional Information About Milestone Pharmaceuticals.

What is Milestone Pharmaceuticals' official website?

The official website for Milestone Pharmaceuticals is http://www.milestonepharma.com/.

How can I contact Milestone Pharmaceuticals?

Milestone Pharmaceuticals' mailing address is 1111 DR. FREDERIK-PHILIPS BLVD SUITE 420, MONTREAL A8, H4M 2X6. The company can be reached via phone at 514-336-0444 or via email at [email protected]


MarketBeat Community Rating for Milestone Pharmaceuticals (NASDAQ MIST)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  29 (Vote Outperform)
Underperform Votes:  30 (Vote Underperform)
Total Votes:  59
MarketBeat's community ratings are surveys of what our community members think about Milestone Pharmaceuticals and other stocks. Vote "Outperform" if you believe MIST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MIST will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/8/2019 by MarketBeat.com Staff

Featured Article: Hedge Funds Explained

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel